Iovance Biotherapeutics, Inc.
(NASDAQ : IOVA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc. -5.78%68.461.0%$1418.97m
BIIBBiogen, Inc. -1.30%306.071.5%$626.44m
REGNRegeneron Pharmaceuticals, Inc. 0.04%431.792.6%$525.20m
AMGNAmgen, Inc. -2.25%198.921.3%$514.57m
ILMNIllumina, Inc. 0.29%260.683.5%$396.99m
VRTXVertex Pharmaceuticals, Inc. -1.23%220.561.9%$344.15m
MRNAModerna, Inc. -12.54%22.880.0%$330.57m
ALXNAlexion Pharmaceuticals, Inc. -0.60%91.542.0%$219.39m
CODXCo-Diagnostics, Inc. -17.48%13.170.0%$204.14m
AAgilent Technologies, Inc. -1.80%76.041.6%$166.72m
EXASEXACT Sciences Corp. 1.69%82.1924.0%$166.39m
BMRNBioMarin Pharmaceutical, Inc. -0.51%89.364.3%$114.15m
INCYIncyte Corp. -2.35%74.062.5%$107.79m
SGENSeattle Genetics, Inc. 0.69%109.066.1%$106.63m
NVAXNovavax, Inc. 19.83%14.14184.0%$78.77m

Company Profile

Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.